Analyst Rami Katkhuda of LifeSci Capital maintained a Buy rating on Amylyx Pharmaceuticals Inc, retaining the price target of $24.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Rami Katkhuda has given his Buy rating due to a combination of factors linked to Amylyx’s lead asset avexitide and the sizable unmet need in post-bariatric hypoglycemia (PBH). His survey of 25 U.S. endocrinologists shows PBH carries substantial clinical burden, with nearly a quarter of patients requiring emergency care, and roughly 45% remaining poorly controlled despite current dietary and off-label drug strategies.
He also notes that most physicians view the demand for new PBH therapies as high and express strong intent to use avexitide across a broad spectrum of PBH severity, implying meaningful commercial uptake if approved. In addition, he views the Phase III LUCIDITY trial as comparatively de-risked, supported by avexitide’s mechanism, prior multi-study data, and robust trial powering, which together enhance confidence in a successful outcome and underpin his positive stance on AMLX shares.